Endocrine Abstracts

Background: Through this study, we hoped to better understand the factors affecting recurrence-free survival in patients who have undergone curative intent resection for small bowel neuroendocrine tumors (SB-NETs). Extensive literature exists on recurrence predictors for pancreatic NETs but not for those of the small bowel. We hope to bridge this gap.Methods: We retrospectively evaluated patients who had received their index curative-intent operation for...

Background: G3 NETs are a recently recognized entity and although the treatment recommendations largely follow those for grade 1 and 2 NETs, the outcomes of therapy are inferior. Little is known about the optimal therapy sequencing but small studies have suggested a benefit of multikinase inhibitors. Somatostatin analogs, PRRT and chemotherapy have all been reported to have activity but later lines of therapy are needed. In this study, we sought to evaluate the activity of cab...

Background: Gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is a rare entity consisting of two morphologically distinct populations of cells, one of which is neuroendocrine and one which is non-neuroendocrine. MiNENs typically contain high grade neuroendocrine carcinoma, conferring a poor prognosis. Due to the rarity of this diagnosis, data is limited and therefore, we sought to add to the current clinical understanding of this diagnosis.<p ...

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have highly heterogeneous growth rates, yielding broad ranges of radiographic imaging intervals in standard guidelines, creating uncertainty for clinicians and patients. Chromogranin A (CgA) is released by GEP-NET cells and has been associated with increased tumor burden. However, clinical utility of CgA measurement has been limited by the lack of prospective validation studies and by different sensitivity for...

Background: Targeted radionuclide therapies (TRTs) have changed the treatment paradigm of neuroendocrine tumors (NET) and are expected to be widely available for patients with various gastroenteropancreatic (GEP)-NET phenotypes. However, while they have great potential, TRT-based therapeutic strategies for high-grade GEP-NET demonstrate variable outcomes, and there is a current lack of tools to identify patients who are likely to respond to TRT. To address this need, the rando...

Background: Poorly differentiated neuroendocrine carcinoma (NEC) is an aggressive malignancy comprising both pulmonary and extrapulmonary primary sites. NEC includes both small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The optimal systemic therapy beyond first line platinum and etoposide is not established. There is a critical need to improve upon the median survival in the second line, as most patients do not survive more than 6 months. The effi...

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...